Ogilvie, Rachel P.
Layton, J. Bradley
Lloyd, Patricia C.
Jiao, Yixin
Djibo, Djeneba Audrey
Wong, Hui Lee
Gruber, Joann F.
Parambi, Ron
Deng, Jie
Miller, Michael
Song, Jennifer
Weatherby, Lisa B.
Peetluk, Lauren
Lo, An-Chi
Matuska, Kathryn
Wernecke, Michael
Bui, Christine L.
Clarke, Tainya C.
Cho, Sylvia
Bell, Elizabeth J.
Yang, Grace
Amend, Kandace L.
Forshee, Richard A.
Anderson, Steven A.
McMahill-Walraven, Cheryl N.
Chillarige, Yoganand
Anthony, Mary S.
Seeger, John D.
Shoaibi, Azadeh
Funding for this research was provided by:
U.S. Food and Drug Administration
Article History
Received: 19 September 2023
Accepted: 11 April 2024
First Online: 26 April 2024
Declarations
:
: This surveillance activity was conducted as part of the FDA public health surveillance mandate and was not subject to Institutional Review Board oversight.
: Not applicable.
: All authors and research partners for this work are collaborators within the FDA Biologics Effectiveness and Safety (BEST) initiative.
: RPO, RP, JD, MM, JS, LBW, LP, EJB, GY, KLA, and JDS are employees of Optum and may own stock in UnitedHealth Group. JBL, CLB, and MSA are employees of RTI International, an independent, not-for-profit research institute that performs research on behalf of governmental and commercial clients, including pharmaceutical and vaccine manufacturers. CNM and DAD are employees of CVS Health. PCL, YJ, HLW, JG, AL, KM, MW, TCC, SC, RAF, SAA, YC, and AS have no conflicts of interest to declare.